REFERENCES
1. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016;278:563-77.
2. Henry T, Sun R, Lerousseau M, et al. Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies. Sci Rep 2022;12:17244.
3. Varghese BA, Cen SY, Hwang DH, Duddalwar VA. Texture analysis of imaging: what radiologists need to know. AJR Am J Roentgenol 2019;212:520-8.
4. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017;14:749-62.
5. Spadarella G, Stanzione A, Akinci D’Antonoli T, et al. Systematic review of the radiomics quality score applications: an EuSoMII radiomics auditing group initiative. Eur Radiol 2023;33:1884-94.
6. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723-50.
7. European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012;48:599-641.
8. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
9. Yao Z, Dong Y, Wu G, et al. Preoperative diagnosis and prediction of hepatocellular carcinoma: radiomics analysis based on multi-modal ultrasound images. BMC Cancer 2018;18:1089.
10. Harding-Theobald E, Louissaint J, Maraj B, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther 2021;54:890-901.
11. Dankerl P, Cavallaro A, Tsymbal A, et al. A retrieval-based computer-aided diagnosis system for the characterization of liver lesions in CT scans. Acad Radiol 2013;20:1526-34.
12. Mokrane FZ, Lu L, Vavasseur A, et al. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. Eur Radiol 2020;30:558-70.
13. Laino ME, Viganò L, Ammirabile A, et al. The added value of artificial intelligence to LI-RADS categorization: a systematic review. Eur J Radiol 2022;150:110251.
14. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis. Pathol Oncol Res 2015;21:131-8.
15. Mao B, Zhang L, Ning P, et al. Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning-based radiomics. Eur Radiol 2020;30:6924-32.
16. Wu M, Tan H, Gao F, et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol 2019;29:2802-11.
17. Huang J, Tian W, Zhang L, et al. Preoperative prediction power of imaging methods for microvascular invasion in hepatocellular carcinoma: a systemic review and meta-analysis. Front Oncol 2020;10:887.
18. Wang Q, Li C, Zhang J, et al. Radiomics models for predicting microvascular invasion in hepatocellular carcinoma: a systematic review and radiomics quality score assessment. Cancers 2021;13:5864.
19. Li L, Wu C, Huang Y, Chen J, Ye D, Su Z. Radiomics for the preoperative evaluation of microvascular invasion in hepatocellular carcinoma: a meta-analysis. Front Oncol 2022;12:831996.
20. Zhong X, Long H, Su L, et al. Radiomics models for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Abdom Radiol 2022;47:2071-88.
21. Yu Y, Fan Y, Wang X, et al. Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma. Eur Radiol 2022;32:959-70.
22. Lee CW, Kuo WL, Yu MC, et al. The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection. World J Surg Oncol 2013;11:136.
23. Wang W, Gu D, Wei J, et al. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol 2020;30:3004-14.
24. Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 2020;294:568-79.
25. Hectors SJ, Lewis S, Besa C, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol 2020;30:3759-69.
26. Kim J, Choi SJ, Lee SH, Lee HY, Park H. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol 2018;211:1026-34.
27. Kloth C, Thaiss WM, Kärgel R, et al. Evaluation of texture analysis parameter for response prediction in patients with hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (DEB-TACE) using biphasic contrast-enhanced ct image data: correlation with liver perfusion CT. Acad Radiol 2017;24:1352-63.
28. Wu LF, Rao SX, Xu PJ, et al. Pre-TACE kurtosis of ADCtotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. Eur Radiol 2019;29:213-23.
29. Shaghaghi M, Aliyari Ghasabeh M, Ameli S, et al. Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up. Eur Radiol 2021;31:1378-90.
30. Yang X, Yuan C, Zhang Y, Li K, Wang Z. Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram. Medicine 2022;101:e32584.
31. Fiz F, Jayakody Arachchige VS, Gionso M, et al. Radiomics of biliary tumors: a systematic review of current evidence. Diagnostics 2022;12:826.
32. Liu X, Khalvati F, Namdar K, et al. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning? Eur Radiol 2021;31:244-55.
33. Zhou C, Wang Y, Ma L, Qian X, Yang C, Zeng M. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol 2022;32:78-88.
34. Ji GW, Zhu FP, Zhang YD, et al. A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. Eur Radiol 2019;29:3725-35.
35. Chu H, Liu Z, Liang W, et al. Radiomics using CT images for preoperative prediction of futile resection in intrahepatic cholangiocarcinoma. Eur Radiol 2021;31:2368-76.
36. Qin H, Hu X, Zhang J, et al. Machine-learning radiomics to predict early recurrence in perihilar cholangiocarcinoma after curative resection. Liver Int 2021;41:837-50.
37. Groot Koerkamp B, Wiggers JK, Allen PJ, et al. American joint committee on cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. HPB 2014;16:1074-82.
38. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-19.
39. Gazzaniga GM, Faggioni A, Filauro M. Surgical treatment of proximal bile duct tumors. Int Surg 1985;70:45-8.
40. Park HJ, Park B, Park SY, et al. Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features. Eur Radiol 2021;31:8638-48.
41. Zhang J, Wu Z, Zhao J, et al. Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. Eur Radiol 2021;31:3661-72.
42. Mosconi C, Cucchetti A, Bruno A, et al. Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation. Eur Radiol 2020;30:4534-44.
43. Fiz F, Viganò L, Gennaro N, et al. Radiomics of liver metastases: a systematic review. Cancers 2020;12:2881.
44. Wesdorp NJ, van Goor VJ, Kemna R, et al. Advanced image analytics predicting clinical outcomes in patients with colorectal liver metastases: a systematic review of the literature. Surg Oncol 2021;38:101578.
45. Jia LL, Zhao JX, Zhao LP, Tian JH, Huang G. Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: a systematic review and meta-analysis. Eur J Radiol 2023;158:110640.
46. Kelahan LC, Kim D, Soliman M, et al. Role of hepatic metastatic lesion size on inter-reader reproducibility of CT-based radiomics features. Eur Radiol 2022;32:4025-33.
47. Ahn SJ, Kim JH, Park SJ, Han JK. Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. Eur J Radiol 2016;85:1867-74.
48. Dercle L, Lu L, Schwartz LH, et al. Radiomics response signature for identification of metastatic colorectal cancer sensitive to therapies targeting EGFR pathway. J Natl Cancer Inst 2020;112:902-12.
49. Dohan A, Gallix B, Guiu B, et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut 2020;69:531-9.
50. Creasy JM, Midya A, Chakraborty J, et al. Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. Eur Radiol 2019;29:458-67.
51. Abunahel BM, Pontre B, Kumar H, Petrov MS. Pancreas image mining: a systematic review of radiomics. Eur Radiol 2021;31:3447-67.
52. Gao Y, Cheng S, Zhu L, et al. A systematic review of prognosis predictive role of radiomics in pancreatic cancer: heterogeneity markers or statistical tricks? Eur Radiol 2022;32:8443-52.
53. Staal FCR, Aalbersberg EA, van der Velden D, et al. GEP-NET radiomics: a systematic review and radiomics quality score assessment. Eur Radiol 2022;32:7278-94.
54. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020;69:7-17.
55. Signoretti M, Bruno MJ, Zerboni G, Poley JW, Delle Fave G, Capurso G. Results of surveillance in individuals at high-risk of pancreatic cancer: a systematic review and meta-analysis. United Eur Gastroent J 2018;6:489-99.
56. Paiella S, Capurso G, Cavestro GM, et al. Results of first-round of surveillance in individuals at high-risk of pancreatic cancer from the AISP (Italian Association for the Study of the Pancreas) registry. Am J Gastroenterol 2019;114:665-70.
57. Chhoda A, Vodusek Z, Wattamwar K, et al. Late-stage pancreatic cancer detected during high-risk individual surveillance: a systematic review and meta-analysis. Gastroenterology 2022;162:786-98.
58. Chu LC, Park S, Kawamoto S, et al. Utility of CT radiomics features in differentiation of pancreatic ductal adenocarcinoma from normal pancreatic tissue. AJR Am J Roentgenol 2019;213:349-57.
59. Qureshi TA, Gaddam S, Wachsman AM, et al. Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images. Cancer Biomark 2022;33:211-7.
60. Javed S, Qureshi TA, Gaddam S, et al. Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images. Front Oncol 2022;12:1007990.
61. Mukherjee S, Patra A, Khasawneh H, et al. Radiomics-based machine-learning models can detect pancreatic cancer on prediagnostic computed tomography scans at a substantial lead time before clinical diagnosis. Gastroenterology 2022;163:1435-46.e3.
62. Jeon SK, Kim JH, Yoo J, Kim JE, Park SJ, Han JK. Assessment of malignant potential in intraductal papillary mucinous neoplasms of the pancreas using MR findings and texture analysis. Eur Radiol 2021;31:3394-404.
63. Chakraborty J, Midya A, Gazit L, et al. CT radiomics to predict high-risk intraductal papillary mucinous neoplasms of the pancreas. Med Phys 2018;45:5019-29.
64. Permuth JB, Choi J, Balarunathan Y, et al. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget 2016;7:85785-97.
65. Zhang H, Meng Y, Li Q, et al. Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis. Eur Radiol 2022;32:6336-47.
66. Wei R, Lin K, Yan W, et al. Computer-aided diagnosis of pancreas serous cystic neoplasms: a radiomics method on preoperative MDCT images. Technol Cancer Res Treat 2019;18:1533033818824339.
67. Chang N, Cui L, Luo Y, Chang Z, Yu B, Liu Z. Development and multicenter validation of a CT-based radiomics signature for discriminating histological grades of pancreatic ductal adenocarcinoma. Quant Imaging Med Surg 2020;10:692-702.
68. Tikhonova VS, Karmazanovsky GG, Kondratyev EV, et al. Radiomics model-based algorithm for preoperative prediction of pancreatic ductal adenocarcinoma grade. Eur Radiol 2023;33:1152-61.
69. Gu D, Hu Y, Ding H, et al. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study. Eur Radiol 2019;29:6880-90.
70. De Robertis R, Maris B, Cardobi N, et al. Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? Eur Radiol 2018;28:2582-91.
71. Mori M, Palumbo D, Muffatti F, et al. Prediction of the characteristics of aggressiveness of pancreatic neuroendocrine neoplasms (PanNENs) based on CT radiomic features. Eur Radiol 2023;33:4412-21.
72. Salinas-Miranda E, Healy GM, Grünwald B, et al. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Eur Radiol 2022;32:6712-22.
73. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531:47-52.
74. Rigiroli F, Hoye J, Lerebours R, et al. CT radiomic features of superior mesenteric artery involvement in pancreatic ductal adenocarcinoma: a pilot study. Radiology 2021;301:610-22.
75. Bian Y, Guo S, Jiang H, et al. Relationship between radiomics and risk of lymph node metastasis in pancreatic ductal adenocarcinoma. Pancreas 2019;48:1195-203.
76. De Robertis R, Geraci L, Tomaiuolo L, et al. Liver metastases in pancreatic ductal adenocarcinoma: a predictive model based on CT texture analysis. Radiol Med 2022;127:1079-84.
77. Tang TY, Li X, Zhang Q, et al. Development of a novel multiparametric MRI radiomic nomogram for preoperative evaluation of early recurrence in resectable pancreatic cancer. J Magn Reson Imaging 2020;52:231-45.
78. De Robertis R, Tomaiuolo L, Pasquazzo F, et al. Correlation between ADC histogram-derived metrics and the time to metastases in resectable pancreatic adenocarcinoma. Cancers 2022;14:6050.
79. Kulkarni A, Carrion-Martinez I, Jiang NN, et al. Hypovascular pancreas head adenocarcinoma: CT texture analysis for assessment of resection margin status and high-risk features. Eur Radiol 2020;30:2853-60.
80. De Robertis R, Beleù A, Cardobi N, et al. Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. Abdom Radiol 2020;45:3809-18.
81. Kim HS, Kim YJ, Kim KG, Park JS. Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer. Sci Rep 2019;9:17389.
82. Xie T, Wang X, Li M, Tong T, Yu X, Zhou Z. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection. Eur Radiol 2020;30:2513-24.
83. Sandrasegaran K, Lin Y, Asare-Sawiri M, Taiyini T, Tann M. CT texture analysis of pancreatic cancer. Eur Radiol 2019;29:1067-73.
84. Healy GM, Salinas-Miranda E, Jain R, et al. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation. Eur Radiol 2022;32:2492-505.
85. Borhani AA, Dewan R, Furlan A, et al. Assessment of response to neoadjuvant therapy using CT texture analysis in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. AJR Am J Roentgenol 2020;214:362-9.
86. Kim BR, Kim JH, Ahn SJ, et al. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol 2019;29:362-72.
